United States Laboratory Equipment and Disposable Market Overview, 2030

The US laboratory equipment and disposables market is deeply intertwined with the country’s well-established life sciences, pharmaceutical, and diagnostics ecosystem. The presence of a vast network of clinical laboratories, academic institutions, and biotechnology firms positions the US as one of the most intensive users of lab technologies globally. In cities like Boston, San Diego, and San Francisco, the concentration of biomedical startups and research centers has created high demand for precision instruments and sterile consumables. Federal research bodies such as the NIH and CDC, along with public health labs, regularly fund infrastructure upgrades that directly contribute to procurement of advanced lab tools. Moreover, public-private collaborations have intensified in recent years, particularly in the wake of infectious disease outbreaks, which have necessitated investments in biosafety-level infrastructure, point-of-care diagnostic equipment, and cold chain storage systems. The increase in next-generation sequencing and gene-editing research has boosted the adoption of automated analyzers, microplate readers, and cryogenic storage units. The trend toward lab automation, especially in high-throughput testing environments, is being observed across diagnostic labs, forensic centers, and academic biocenters. Facilities are upgrading their equipment not just for technical performance, but also for compatibility with digital lab management platforms, which streamline workflows and enhance regulatory compliance. Enhanced focus on sustainability is also pushing manufacturers to develop energy-efficient systems and recyclable components to meet institutional ESG mandates.

According to the research report ""US Laboratory Equipment and Disposables Market Overview, 2030,"" published by Bonafide Research, the US Laboratory Equipment and Disposables market is anticipated to grow at more than 5.20% CAGR from 2025 to 2030. Several interconnected factors are accelerating the growth of the laboratory equipment and disposables market in the US. Key among them is the significant shift toward personalized medicine, which is expanding the number of complex laboratory tests needed for patient stratification, biomarker validation, and therapy monitoring. This has increased the adoption of sample prep systems, multiplex analyzers, and disposable assay platforms in oncology and immunology labs. The increasing use of biologics, mRNA therapies, and cell-based treatments has led to higher demand for closed-system instruments and single-use components that preserve sample integrity and prevent cross-contamination. Regional biotech clusters, including Research Triangle Park in North Carolina and Montgomery County in Maryland, are investing in modular lab spaces that require scalable instrumentation and disposables for pilot-scale and commercial R&D projects. Academic institutions and university medical centers are expanding interdisciplinary programs in nanobiotech, proteomics, and regenerative medicine, each with highly specialized equipment needs. A noticeable trend is the rapid adoption of compact, portable instruments in mobile and field labs, which are critical for rural diagnostics, environmental assessments, and outbreak investigations. Compliance-driven procurement patterns driven by agencies such as the FDA, CLIA, and OSHA are pushing labs to adopt instruments that feature embedded quality controls, automated calibration, and compatibility with audit trails. Labs are also under growing pressure to operate cost-efficiently, leading to increased reliance on pre-filled, ready-to-use consumables that eliminate the need for additional cleaning, sterilization, or reassembly. Emerging innovations in microfluidics and lab-on-chip technologies are contributing to a new wave of compact systems with disposable elements tailored for specific assays or workflows.

In the US, laboratory equipment dominates the market in terms of procurement value due to the strategic, long-term investment approach taken by research institutions and commercial labs. Advanced equipment like high-resolution mass spectrometers, automated ELISA platforms, and digital pathology scanners are extensively utilized across pharma and academic labs engaged in high-stakes research. Pharmaceutical companies prioritize instruments with advanced sensitivity and throughput to support fast-track development pipelines, particularly in therapeutic areas like rare diseases and immunotherapies. Demand for integrated systems such as automated sample-to-result analyzers and cloud-enabled sequencer is rising in core and satellite labs to streamline operations. Despite this, disposables are growing at a faster pace due to increased testing volumes and the rise in infection control protocols. Daily consumables such as pipette tips, centrifuge tubes, filtration membranes, and PCR plates are replenished frequently across diagnostic, academic, and biotech labs. The push for traceability and reduced contamination risks is encouraging the use of individually barcoded and sterile-packaged disposables. In clinical diagnostics, especially in high-volume COVID-19, RSV, and influenza testing, labs shifted to fully disposable workflows to manage surge testing without compromising biosafety. Laboratories in underserved regions of the US are adopting affordable, single-use kits that are compact, durable, and suitable for transit conditions. There’s also growing exploration of biodegradable consumables among university-based green labs, especially on campuses with sustainability initiatives. Still, scalability and cost remain limiting factors in broader adoption.

The pharmaceutical industry is the most significant consumer of lab infrastructure in the US, fueled by drug discovery pipelines and preclinical trial activities. Their use cases often demand precision instrumentation, validated disposables, and real-time monitoring tools to meet rigorous standards in pharmacokinetics, toxicology, and bioanalytical testing. Large-cap pharma companies in New Jersey, Connecticut, and Pennsylvania are investing in modular lab automation systems and high-efficiency sample handling tools to improve time-to-market for new drugs. Meanwhile, the biotechnology sector, concentrated in California and Massachusetts, is witnessing the fastest growth in demand for disposables. These companies typically operate in dynamic environments where single-use systems reduce setup time and lower the risk of cross-contamination. Hospitals and clinical diagnostic labs, particularly in large urban systems like NYU Langone or Cleveland Clinic, focus on rapid processing capabilities. They use high-throughput instruments and rely heavily on pre-packaged consumables for pathology, hematology, and infectious disease screening. Academic and government-funded research institutions require a broad range of general-purpose instruments such as spectrophotometers, laminar flow cabinets, and cold storage solutions. Their equipment needs are often met through grant funding cycles or through technology partnerships with equipment providers. Additionally, labs within industrial sectors including environmental testing labs, food quality labs, and forensic analysis centers demand equipment that supports continuous testing and compliance with standards like ISO 17025. These facilities favor rugged, easy-to-service instruments and disposable components that ensure sample reproducibility and traceability.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Laboratory Equipment and Disposable Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Equipment
• Disposables

By End-User
• Pharmaceuticals
• Hospitals
• Academic/Research
• Biotech
• Industrial Show more